{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:45:56Z","timestamp":1791999956888,"version":"4.4.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1016\/j.vaccine.2009.09.114","type":"journal-article","created":{"date-parts":[[2009,10,9]],"date-time":"2009-10-09T11:08:16Z","timestamp":1255086496000},"page":"53-62","source":"Crossref","is-referenced-by-count":86,"title":["Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis"],"prefix":"10.1016","volume":"28","author":[{"given":"Amir","family":"Mizbani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahereh","family":"Taheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farnaz","family":"Zahedifard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasaman","family":"Taslimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiva","family":"Azizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayhan","family":"Azadmanesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Papadopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sima","family":"Rafati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2009.09.114_bib1","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1093\/infdis\/154.6.1003","article-title":"New perspectives on a subclinical form of visceral leishmaniasis","volume":"154","author":"Badaro","year":"1986","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2009.09.114_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/clinids\/22.1.1","article-title":"Clinical spectrum of leishmaniasis","volume":"22","author":"Pearson","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2009.09.114_bib3","unstructured":"Desjeux P. Leishmania and HIV in gridlock. Publication nos. WHO\/CTD\/LEISH\/98.9, UNAIDS\/98.23. Geneva: World Health Organization; 1998."},{"key":"10.1016\/j.vaccine.2009.09.114_bib4","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.cimid.2004.03.004","article-title":"Leishmaniasis: current situation and new perspectives","volume":"27","author":"Desjeux","year":"2004","journal-title":"Comp Immunol Microbiol Infect Dis"},{"key":"10.1016\/j.vaccine.2009.09.114_bib5","series-title":"The leishmaniasis in biology and medicine","article-title":"Introduction","author":"Graham","year":"1987"},{"key":"10.1016\/j.vaccine.2009.09.114_bib6","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S0140-6736(98)10178-2","article-title":"Leishmaniasis","volume":"354","author":"Herwaldt","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2009.09.114_bib7","first-page":"1","article-title":"Leishmania\/HIV co-infection in South-Western Europe 1990\u20131998: retrospective analysis of 965 cases, Geneva","volume":"42","author":"World Health Organization","year":"2000","journal-title":"WHO\/LEISH\/2000"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2009.09.114_bib8","first-page":"S17","article-title":"Leishmania\/HIV co-infections: epidemiology in Europe","volume":"97","author":"Desjeux","year":"2003","journal-title":"Ann Trop Med Parasitol"},{"key":"10.1016\/j.vaccine.2009.09.114_bib9","first-page":"407","article-title":"Diagnosis & management of Leishmania\/HIV co-infection","volume":"121","author":"Sinha","year":"2005","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.vaccine.2009.09.114_bib10","first-page":"2","article-title":"Advances in the battle against leishmaniasis","volume":"57","author":"World Health Organization","year":"1998","journal-title":"TDR News"},{"key":"10.1016\/j.vaccine.2009.09.114_bib11","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/0165-6147(88)90258-1","article-title":"Recent development in the chemotherapy of leishmaniasis","volume":"9","author":"Croft","year":"1988","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.vaccine.2009.09.114_bib12","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/infdis\/157.5.973","article-title":"Immunochemotherapy for intracellular Leishmania donovani infection: \u03b3-interferon plus pentavalent antimony","volume":"157","author":"Murray","year":"1988","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2009.09.114_bib13","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1128\/AAC.47.5.1529-1535.2003","article-title":"The in vivo susceptibility of Leishmania donovani to sodium stibogluconate is drug specific and can be reversed by inhibiting glutathione biosynthesis","volume":"47","author":"Carter","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.vaccine.2009.09.114_bib14","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1128\/AAC.47.8.2397-2403.2003","article-title":"Leishmania donovani resistance to miltefosine involves a defective inward translocation of the drug","volume":"47","author":"P\u00e9rez-Victoria","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.vaccine.2009.09.114_bib15","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1475-9292-2-14","article-title":"Physiological consequences of drug resistance in Leishmania and their relevance for chemotherapy","volume":"2","author":"Ponte-Sucre","year":"2003","journal-title":"Kinetoplastid Biol Dis"},{"key":"10.1016\/j.vaccine.2009.09.114_bib16","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1046\/j.1365-3156.2001.00778.x","article-title":"Drug resistance in Indian visceral leishmaniasis","volume":"6","author":"Sundar","year":"2001","journal-title":"Trop Med Int Health"},{"key":"10.1016\/j.vaccine.2009.09.114_bib17","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1086\/318121","article-title":"Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic","volume":"31","author":"Sundar","year":"2000","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2009.09.114_bib18","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1080\/00034983.1995.11813017","article-title":"Vaccines against leishmaniasis","volume":"89","author":"Modabber","year":"1995","journal-title":"Ann Trop Med Parasitol"},{"key":"10.1016\/j.vaccine.2009.09.114_bib19","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1128\/CMR.14.2.229-243.2001","article-title":"Leishmaniasis: current status of vaccine development","volume":"14","author":"Handman","year":"2001","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2009.09.114_bib20","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2174\/1566524043360203","article-title":"Leishmaniasis: current status of vaccine development","volume":"4","author":"Sukumaran","year":"2004","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.vaccine.2009.09.114_bib21","doi-asserted-by":"crossref","first-page":"11473","DOI":"10.1073\/pnas.90.24.11473","article-title":"Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guerin expressing the Leishmania surface proteinase gp63","volume":"90","author":"Connell","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2009.09.114_bib22","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1365-2249.1991.tb05663.x","article-title":"Analysis of the human T cell responsiveness to purified antigens of Leishmania: lipophosphoglycan (LPG) and glycoprotein 63 (gp 63)","volume":"83","author":"Mendonca","year":"1991","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.vaccine.2009.09.114_bib23","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1128\/IAI.61.8.3351-3359.1993","article-title":"Recombinant vaccinia viruses expressing GP46\/M-2 protect against Leishmania infection","volume":"61","author":"McMahon-Pratt","year":"1993","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2009.09.114_bib24","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1084\/jem.186.7.1137","article-title":"Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major","volume":"186","author":"Gurunathan","year":"1997","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2009.09.114_bib25","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1126\/science.7725103","article-title":"Expression cloning of a protective Leishmania antigen","volume":"268","author":"Mougneau","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2009.09.114_bib26","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1046\/j.1365-2249.2000.01160.x","article-title":"Vaccination of BALB\/c mice with Leishmania major amastigote-specific cysteine proteinase","volume":"120","author":"Rafati","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.vaccine.2009.09.114_bib27","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0264-410X(00)00207-3","article-title":"Immunization with recombinant LD1 antigens protects against experimental leishmaniasis","volume":"19","author":"Dole","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.09.114_bib28","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1128\/IAI.63.11.4261-4267.1995","article-title":"Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response","volume":"63","author":"Handman","year":"1995","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2009.09.114_bib29","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1016\/S0264-410X(02)00302-X","article-title":"Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant","volume":"20","author":"Skeiky","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.09.114_bib30","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1128\/IAI.66.7.3279-3289.1998","article-title":"Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family","volume":"66","author":"Webb","year":"1998","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2009.09.114_bib31","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.vaccine.2004.07.044","article-title":"Protective immunogenicity of the paraflagellar rod protein 2 of Leishmania mexicana","volume":"23","author":"Saravia","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.09.114_bib32","doi-asserted-by":"crossref","first-page":"7064","DOI":"10.4049\/jimmunol.165.12.7064","article-title":"Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis","volume":"165","author":"Stager","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2009.09.114_bib33","doi-asserted-by":"crossref","first-page":"6171","DOI":"10.4049\/jimmunol.161.11.6171","article-title":"LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile","volume":"161","author":"Skeiky","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2009.09.114_bib34","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1128\/IAI.63.5.2062-2069.1995","article-title":"A recombinant Leishmania chagasi antigen that stimulates cellular immune responses in infected mice","volume":"63","author":"Wilson","year":"1995","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2009.09.114_bib35","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1128\/IAI.56.12.3272-3279.1988","article-title":"Membrane glycoprotein M-2 protects against Leishmania amazonensis infection","volume":"56","author":"Champsi","year":"1988","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2009.09.114_bib36","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pt.2005.03.006","article-title":"Second-generation vaccines against leishmaniasis","volume":"21","author":"Coler","year":"2005","journal-title":"Trends Parasitol"},{"key":"10.1016\/j.vaccine.2009.09.114_bib37","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/S0140-6736(05)67629-5","article-title":"Advances in leishmaniasis","volume":"366","author":"Murray","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2009.09.114_bib38","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.4049\/jimmunol.163.3.1467","article-title":"Protective immune responses induced by vaccination with an expression genomic library of Leishmania major","volume":"163","author":"Piedrafita","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2009.09.114_bib39","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nature01152","article-title":"CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity","volume":"420","author":"Belkaid","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2009.09.114_bib40","doi-asserted-by":"crossref","first-page":"6967","DOI":"10.4049\/jimmunol.167.12.6967","article-title":"Immune elimination of Leishmania major in mice: implications for immune memory, vaccination, and reactivation disease","volume":"167","author":"Uzonna","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2009.09.114_bib41","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1046\/j.1365-3024.1999.00244.x","article-title":"Vaccination against Leishmania major in a CBA mouse model of infection: role of adjuvants and mechanism of protection","volume":"21","author":"Rivier","year":"1999","journal-title":"Parasite Immunol"},{"key":"10.1016\/j.vaccine.2009.09.114_bib42","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/icb.1984.14","article-title":"Vaccination against cutaneous leishmaniasis in mice using nonpathogenic cloned promastigotes of Leishmania major and importance of route of injection","volume":"62","author":"Mitchell","year":"1984","journal-title":"Aust J Exp Biol Med Sci"},{"key":"10.1016\/j.vaccine.2009.09.114_bib43","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0008-8749(85)90081-4","article-title":"Immunization of susceptible BALB\/c mice against Leishmania braziliensis. II. Use of temperature-sensitive avirulent clones of parasite for vaccination purposes","volume":"94","author":"Gorczynski","year":"1985","journal-title":"Cell Immunol"},{"key":"10.1016\/j.vaccine.2009.09.114_bib44","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.1128\/IAI.61.12.5205-5213.1993","article-title":"An avirulent lipophosphoglycan-deficient Leishmania major clone induces CD4+ T cells which protect susceptible BALB\/c mice against infection with virulent L. major","volume":"61","author":"Kimsey","year":"1993","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2009.09.114_bib45","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1086\/374783","article-title":"Leishmania mexicana and Leishmania major: attenuation of wild-type parasites and vaccination with the attenuated lines","volume":"187","author":"Daneshvar","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2009.09.114_bib46","doi-asserted-by":"crossref","first-page":"10267","DOI":"10.1073\/pnas.92.22.10267","article-title":"Development of a safe live Leishmania vaccine line by gene replacement","volume":"92","author":"Titus","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2009.09.114_bib47","doi-asserted-by":"crossref","first-page":"6794","DOI":"10.4049\/jimmunol.161.12.6794","article-title":"Leishmania mexicana cysteine proteinase-deficient mutants have attenuated virulence for mice and potentiate a Th1 response","volume":"161","author":"Alexander","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2009.09.114_bib48","doi-asserted-by":"crossref","first-page":"5987","DOI":"10.1128\/MCB.17.10.5987","article-title":"Leishmania major Hsp100 is required chiefly in the mammalian stage of the parasite","volume":"17","author":"H\u00fcbel","year":"1997","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.vaccine.2009.09.114_bib49","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.4049\/jimmunol.179.5.3161","article-title":"SIR2-deficient Leishmania infantum induces a defined IFN-\u03b3\/IL-10 pattern that correlates with protection","volume":"179","author":"Silvestre","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2009.09.114_bib50","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.4049\/jimmunol.172.6.3793","article-title":"Vaccination with phosphoglycan-deficient Leishmania major protects highly susceptible mice from virulent challenge without inducing a strong Th1 response","volume":"172","author":"Uzonna","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2009.09.114_bib51","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1128\/IAI.70.1.62-68.2002","article-title":"Reduced infectivity of a Leishmania donovani biopterin transporter genetic mutant and its use as an attenuated strain for vaccination","volume":"70","author":"Papadopoulou","year":"2002","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2009.09.114_bib52","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1093\/emboj\/16.10.2590","article-title":"Disruption of the trypanothione reductase gene of Leishmania decreases its ability to survive oxidative stress in macrophages","volume":"16","author":"Dumas","year":"1997","journal-title":"EMBO J"},{"key":"10.1016\/j.vaccine.2009.09.114_bib53","doi-asserted-by":"crossref","first-page":"6372","DOI":"10.1128\/IAI.73.10.6372-6382.2005","article-title":"Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis","volume":"73","author":"Breton","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2009.09.114_bib54","series-title":"Biology of the Kinetoplastida","first-page":"244","article-title":"Lizard leishmania","author":"Wilson","year":"1978"},{"key":"10.1016\/j.vaccine.2009.09.114_bib55","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1099\/vir.0.81995-0","article-title":"A recombinant non-pathogenic Leishmania vaccine expressing human immunodeficiency virus 1 (HIV-1) Gag elicits cell-mediated immunity in mice and decreases HIV-1 replication in human tonsillar tissue following exposure to HIV-1 infection","volume":"88","author":"Breton","year":"2007","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2009.09.114_bib56","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1017\/S0031182009005873","article-title":"Searching for virulence factors in the non-pathogenic parasite to humans Leishmania tarentolae","volume":"136","author":"Azizi","year":"2009","journal-title":"Parasitology"},{"key":"10.1016\/j.vaccine.2009.09.114_bib57","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1128\/MCB.14.5.2975","article-title":"Developmental gene expression in Leishmania donovani: differential cloning and analysis of an amastigotestage-specific gene","volume":"14","author":"Charest","year":"1994","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.vaccine.2009.09.114_bib58","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0166-6851(96)02612-6","article-title":"Identification and overexpression of the A2 amastigote-specific protein in Leishmania donovani","volume":"78","author":"Zhang","year":"1996","journal-title":"Mol Biochem Parasitol"},{"key":"10.1016\/j.vaccine.2009.09.114_bib59","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1128\/CDLI.4.5.530-535.1997","article-title":"Antibody response against a Leishmania donovani amastigote-stage-specific protein in patients with visceral leishmaniasis","volume":"4","author":"Ghedin","year":"1997","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2009.09.114_bib60","doi-asserted-by":"crossref","first-page":"5888","DOI":"10.1016\/j.vaccine.2008.05.095","article-title":"Protective immunity against challenge with Leishmania (Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein","volume":"26","author":"Fernandes","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.09.114_bib61","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1128\/IAI.71.7.3988-3994.2003","article-title":"Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection","volume":"71","author":"Ferraz Coelho","year":"2003","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2009.09.114_bib62","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1016\/S0264-410X(01)00023-8","article-title":"Protection against Leishmania donovani infection by DNA vaccination: increased DNA vaccination efficiency through inhibiting the cellular p53 response","volume":"19","author":"Ghosh","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.09.114_bib63","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0264-410X(01)00322-X","article-title":"Immunization with A2 protein results in amixed Th1\/Th2 and a humoral response which protects mice against Leishmania donovani infections","volume":"20","author":"Ghosh","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.09.114_bib64","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1016\/j.vaccine.2008.05.091","article-title":"Epitope mapping and protective immunity elicited by adenovirus expressing the Leishmania amastigote specific A2 antigen: Correlation with IFN-\u03b3 and cytolytic activity by CD8+ T cells","volume":"26","author":"Resende","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.09.114_bib65","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.micinf.2007.05.012","article-title":"Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against Leishmania chagasi and Leishmania amazonensis experimental infections","volume":"9","author":"Zanin","year":"2007","journal-title":"Microbes Infect"},{"key":"10.1016\/j.vaccine.2009.09.114_bib66","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.molbiopara.2005.01.006","article-title":"Characterization and developmental gene regulation of a large gene family encoding amastin surface proteins in Leishmania spp.","volume":"140","author":"Rochette","year":"2005","journal-title":"Mol Biochem Parasitol"},{"key":"10.1016\/j.vaccine.2009.09.114_bib67","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1002\/j.1460-2075.1992.tb05444.x","article-title":"A novel antifolate resistance gene on the amplified H circle of Leishmania","volume":"11","author":"Papadopoulou","year":"1992","journal-title":"EMBO J"},{"key":"10.1016\/j.vaccine.2009.09.114_bib68","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0065-308X(08)60208-0","article-title":"Immunology of leishmaniasis","volume":"32","author":"Liew","year":"1993","journal-title":"Adv Parasitol"},{"key":"10.1016\/j.vaccine.2009.09.114_bib69","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1128\/IAI.62.3.1058-1063.1994","article-title":"Th1 and Th2 cell-associated cytokines in experimental visceral leishmaniasis","volume":"62","author":"Miralles","year":"1994","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2009.09.114_bib70","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1574-695X.2007.00311.x","article-title":"Immune response to Leishmania: paradox rather than paradigm","volume":"51","author":"Tripathi","year":"2007","journal-title":"FEMS Immunol Med Microbiol"},{"key":"10.1016\/j.vaccine.2009.09.114_bib71","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1590\/S0074-02762002000700019","article-title":"Study of the safety, immunogenicity and efficacy of attenuated and killed Leishmania (Leishmania) major vaccines in a rhesus monkey (Macaca mulatta) model of the human disease","volume":"97","author":"Amaral","year":"2002","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"10.1016\/j.vaccine.2009.09.114_bib72","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1046\/j.1365-2249.2001.01501.x","article-title":"Differential induction of cellular responses by live and dead Leishmania promastigotes in healthy donors","volume":"124","author":"Nyl\u00e9n","year":"2001","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.vaccine.2009.09.114_bib73","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1016\/j.vaccine.2009.01.133","article-title":"Qualitative differences in the early immune response to live and killed Leishmania major: Implications for vaccination strategies against Leishmaniasis","volume":"27","author":"Okwor","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.09.114_bib74","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1084\/jem.20040298","article-title":"Role for CD4+ CD25+ regulatory T cells in reactivation of persistent Leishmaniasis and control of concomitant immunity","volume":"200","author":"Mendez","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2009.09.114_bib75","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1046\/j.1365-2958.2001.02286.x","article-title":"Characterization of the A2-A2rel gene cluster in Leishmania donovani: involvement of A2 in visceralization during infection","volume":"39","author":"Zhang","year":"2001","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.vaccine.2009.09.114_bib76","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1146\/annurev.iy.04.040186.002101","article-title":"Current status of immunological adjuvants","volume":"4","author":"Warren","year":"1986","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.vaccine.2009.09.114_bib77","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1126\/science.3107127","article-title":"Interferon-\u03b3 and B cell stimulatory factor-1 reciprocally regulate Ig isotype production","volume":"236","author":"Snapper","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2009.09.114_bib78","doi-asserted-by":"crossref","first-page":"7160","DOI":"10.4049\/jimmunol.174.11.7160","article-title":"Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis","volume":"174","author":"Basu","year":"2005","journal-title":"Immunology"},{"key":"10.1016\/j.vaccine.2009.09.114_bib79","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s00436-008-1150-x","article-title":"Effect of dose and route of inoculation on the generation of CD4+ Th1\/Th2 type of immune response in murine visceral leishmaniasis","volume":"103","author":"Kaur","year":"2008","journal-title":"Parasitol Res"},{"key":"10.1016\/j.vaccine.2009.09.114_bib80","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1128\/IAI.01739-07","article-title":"Vaccination route that induces transforming growth factor beta production fails to elicit protective immunity against Leishmania donovani infection","volume":"77","author":"Bhowmick","year":"2009","journal-title":"Infect Immun"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X09014741?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X09014741?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T03:07:24Z","timestamp":1685156844000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X09014741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":80,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["S0264410X09014741"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2009.09.114","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}